Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UP-NEXT: upifitamab rilsodotin maintenance after platinum for recurrent platinum-sensitive ovarian cancer
NL-OMON53654Phase 3Not yet recruiting
- Sponsor
- Mersana Therapeutics
- Start
- Apr 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer comparing Upifitamab rilsodotin maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival by blinded independent central review. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
upifitamab rilsodotin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NL-OMON53654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53654.